Halozyme Therapeutics Inc

HALO

Equity

ISIN null / Valor 1814799

NASDAQ (2026-02-20)

USD 70.98-1.47%

Halozyme Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Halozyme Therapeutics Inc is a biopharmaceutical company that specializes in developing and commercializing novel drug delivery technologies. With over three decades of experience, the company has broadened its technological offerings to include a variety of auto-injectors for subcutaneous and intramuscular administration, catering to specific patient and therapeutic requirements. At the core of Halozyme's innovation is its ENHANZE® drug delivery technology, which leverages the proprietary enzyme rHuPH20 to enhance the subcutaneous delivery of injectable drugs and fluids. This technology has been commercially validated and is notable for its potential to significantly improve patient experience by transforming lengthy IV infusions into quick subcutaneous injections. Through its focus on creating custom-designed drug delivery devices and its ENHANZE® platform, Halozyme aims to address and reduce the treatment burden for patients across various therapeutic areas.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

23.6%1Y

41.9%3Y

42.9%5Y

Performance

44.0%1Y

42.1%3Y

40.4%5Y

Volatility